GammaTile

What GammaTile does

GT Medical Technologies, Inc., operating as GammaTile, is a privately held medical device company headquartered in Tempe, Arizona that develops and commercializes GammaTile, the first and only FDA-cleared tile-based radiation therapy (TBRT) for operable brain tumors. The product is a bioresorbable collagen tile embedded with four cesium-131 (Cs-131) radioactive seeds that is implanted at the time of brain tumor resection surgery, delivering approximately 88% of its therapeutic radiation dose within 30 days and eliminating the typical 2-8 week post-operative delay associated with external beam radiation therapy. The company was founded in the early 2010s by five brain tumor specialists (Brachman, McBride, Nakaji, Youssef, and Thomas) and achieved full U.S. market launch in March 2020 after FDA clearance for newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms, including glioblastoma, brain metastases, and recurrent meningiomas.

The technology's distinguishing features include uniform source spacing within the collagen matrix for predictable dosimetry, a 3mm offset between seeds and the tile surface to protect healthy brain tissue, a cesium-131 half-life of 9.7 days, and bioresorbability that eliminates the need for surgical removal. Clinical evidence supporting the device includes peer-reviewed local control rates of 80-100% at 12 months across indications, a 0% reoperation rate for GammaTile-related radiation necrosis, and positive Phase 3 ROADS RCT results presented at ASCO 2026 demonstrating superior tumor control and overall survival compared to post-surgical stereotactic radiotherapy for newly diagnosed brain metastases. The company runs an active clinical development program spanning the ROADS, GESTALT, and BRIDGES trials with leading academic centers including MD Anderson and Memorial Sloan Kettering.

GammaTile generates revenue through direct hardware sales of the medical device to hospitals and cancer centers performing brain tumor resection, billed under Medicare MS-DRG 023 and Revenue Code 0278. The commercial motion is enterprise field sales targeting neurosurgeons and radiation oncologists at academic medical centers, supported by a dedicated ordering portal, medical affairs proctoring, and reimbursement consulting. The company operates a Centers of Excellence program with 20+ designated sites across the United States and has treated 2,000+ patients cumulatively as of August 2025. Through 2025-2026 the company completed a $53M Series D and an oversubscribed $100M Series E financing to fund continued commercial expansion.

Name

GammaTile

Legal name

GT Medical Technologies, Inc.

Website

https://gammatile.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

GT Medical Technologies develops and commercializes GammaTile, an FDA-cleared bioresorbable collagen tile embedded with cesium-131 radiation seeds implanted during brain tumor resection. The device is sold directly to U.S. hospitals and cancer centers treating operable brain tumors.

Ownership category

akta.pro rank

Product category

Radiation Therapy Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Brachytherapy devices
• Radiation oncology products
• Neurosurgical implants
• Brain tumor therapy
• Collagen tile implants

Headquarters

HQ city

Tempe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. GammaTile Medical Device Sales: GammaTile is sold as a medical device (bioresorbable collagen tile embedded with cesium-131 radioactive seeds) to hospitals and treatment centers for implantation during brain tumor resection surgery. Revenue is generated through direct device sales to healthcare institutions, billed via hospital chargemaster under Revenue Code 0278 (OR Supplies Implant). Coverage exists under Medicare MS-DRG 023 for craniotomy with major device implant.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

GammaTile is a surgically implantable, bioresorbable collagen tile embedded with four cesium-131 (Cs-131) radioactive seeds that is placed at the time of brain tumor resection surgery to deliver targeted, immediate radiation therapy directly to the tumor cavity. The product is FDA-cleared for newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms, eliminating the traditional 2-8 week post-operative external beam radiation delay. It is sold as a medical device directly to hospitals, academic medical centers, and cancer treatment centers across the United States.

Product overview

GammaTile is a single FDA-cleared medical device product — a surgically implantable, bioabsorbable tile-based radiation therapy. The GammaTile product consists of bioresorbable collagen tiles embedded with four cesium-131 (Cs-131) radiation seeds each. Tiles are placed at the time of tumor resection surgery and deliver targeted radiation directly to the tumor cavity. The company also offers supporting services including a GammaTile Ordering Portal, Cavity Surface Area Calculator for tile estimation, Lookup Tables, a Centers of Excellence program for treatment centers, coding and reimbursement guidance, and a GammaTile Commitment Pledge for recurrent tumors. GT Medical Technologies, the parent company, develops this single product focus along with clinical trial programs (ROADS, GESTALT, BRIDGES) and a patient registry.

Differentiator

Problem solved

Functional benefit

Products and services

• GammaTile Tile-Based Radiation Therapy (TBRT) FDA-cleared bioresorbable collagen tile embedded with four cesium-131 radiation seeds, surgically implanted at the time of brain tumor removal to deliver targeted radiation therapy directly to the tumor cavity. Indicated for patients with newly diagnosed malignant and recurrent operable brain tumors including glioblastoma, brain metastases, and meningiomas. Sold as a medical device to hospitals and treatment centers.

Quantifiable outcome

• In ROADS Phase 3 RCT: cancer was less likely to grow back in the treated area; patients were less likely to have worrisome changes on follow-up brain MRIs; patients lived longer; treatment did not increase the chance of side effects
• +6 more outcomes

Named customers13 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• BRIDGES Trial InvestigatorscoreStrategic or Co-development Partner · 14 January 2026The BRIDGES trial is evaluating GammaTile for newly diagnosed glioblastoma. First patients treated January 2026. Building on the GESTALT trial (NCT05342883, enrollment complete) which evaluated GammaTile combined with standard external beam radiation and chemotherapy.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 March 2020MD Anderson Cancer Center serves as the lead institution for the ROADS (Randomized controlled trial Of resection plus post-operative stereotactic radiation versus resection plus cesium-131 tile-based radiation therapy for newly diagnosed brain metastases) Phase 3 randomized clinical trial (NCT04365374). ROADS results were presented at ASCO 2026.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerMemorial Sloan Kettering Cancer Center is the sponsor and lead institution for a Phase II randomized clinical trial (NCT04690348) evaluating intracavity carrier-embedded Cs-131 brachytherapy (GammaTile) for recurrent brain metastases.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Brainlab: Provides neurosurgical navigation, radiosurgery planning software (Elements), and intraoperative imaging used by neurosurgeons who implant GammaTile — overlapping customer base and complementary technology positioning.
• Elekta: Global leader in radiation therapy hardware (linacs, Gamma Knife, brachytherapy afterloaders) and software — competes with GammaTile across the brain tumor radiotherapy workflow, including Gamma Knife SRS as a key alternative.
• Mevion Medical Systems: Manufactures compact proton therapy systems used in select brain tumor treatments — competing modality in the neuro-oncology radiation therapy space.
• Varian (a Siemens Healthineers company): Provides linacs, Eclipse treatment planning, and brachytherapy solutions; competes with GammaTile as part of broader radiation oncology portfolio in neuro-oncology settings.

Direct peers

• Novocure: Markets Tumor Treating Fields (Optune) for newly diagnosed and recurrent glioblastoma — directly competing with GammaTile in the same neuro-oncology indication and physician call point.
• Isoray (formerly IsoRay Medical): Produces Cesium-131 (GammaTile's isotope) and other brachytherapy seeds (I-125, Pd-103) used in competing brain and prostate brachytherapy protocols — overlapping isotope technology and clinical use cases.
• Accuray: Manufactures CyberKnife and TomoTherapy stereotactic radiotherapy systems, the principal post-operative SRS alternative against which GammaTile was benchmarked in the ROADS Phase 3 trial.

Emerging players

• Plus Therapeutics: Developing targeted radiotherapeutic (Rhenium-186 NanoLiposome) for recurrent glioblastoma and leptomeningeal disease — competes in the same brain tumor radiation therapy category with a different isotope/format.
• RefleXion Medical: Developing biology-guided radiotherapy (BgRT) using PET signals during treatment — emerging radiation oncology competitor targeting similar solid tumor indications, including potential brain metastases applications.
• ViewRay (now part of ViewRay Technologies / acquired by Elekta): Developed MR-guided radiotherapy (MRIdian) systems providing intra-fraction imaging — represents an adjacent technology alternative to GammaTile's intraoperative brachytherapy approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/gt-medical-technologies-inc
• Xx.com/GammaTile
• Facebookfacebook.com/GammaTile

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GammaTile